Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder
PRINCETON, N.J., April 7, 2025 /PRNewswire/ — Luye Pharma Group today announced…
/R E P E A T — MEDIA ADVISORY – Canada's No. 1 Hospital to announce strategy to attract world's most promising scientists to drive health innovation and economic growth/
TORONTO, April 6, 2025 /PRNewswire/ — WHAT: Canada’s No. 1 Hospital, University Health…